Published Date: 14 Apr 2023
A tumor suppressor gene called TP53 effectively restricts the development and growth of many different types of tumors in the human body, and this...
Read Full NewsA phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.
In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.
A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.
Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma
Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention
6 Ophthalmology Headlines You Missed in October 2025
1.
Research discovery halts childhood brain tumor before it forms
2.
Can taking vitamin D supplements every day lower the mortality rate from cancer?
3.
Transplantation Fails to Improve Survival in Mantle Cell Lymphoma
4.
Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.
5.
a cutting-edge cancer diagnostic tool.
1.
Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care
2.
What is Hemorrhagic Cystitis and How to Manage its Symptoms
3.
Liquid Biopsy: A Game-Changer in T-Cell Lymphoma Detection and Management
4.
The Genetics of Bernard Soulier Syndrome: What We Know so Far
5.
Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A New Era in Managing Cancer-Associated Thrombosis
2.
Navigating the Complexities of Ph Negative ALL - Part II
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation